AveXis, a Novartis company, has signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont, CO, further expanding AveXis’ production capacity as it prepares to launch Zolgensma (onasemnogene abeparvovec-xioi1) an investigational gene therapy awaiting global regulatory approvals for the treatment of spinal muscular atrophy (SMA) Type 1 and for future gene therapy treatments in development.   AveXis currently has a fully-operational state-of-the-art manufa...